Do You Have Any Questions?
Improve efficiency, provide a better customer experience with modern technology services available around the world. Our skilled staff, combined with decades of experience.
At Transparon, we stand as a leading provider of pharmaceutical and biopharmaceutical regulatory services. Our extensive array of offerings spans the entire spectrum of regulatory needs, encompassing services such as regulatory strategy development, dossier preparation, clinical trial support, compliance consulting, and assistance with post-approval modifications. Our expertise extends across diverse domains, including CMC, clinical regulatory affairs, medical writing, agency negotiations, and our proven track record in expediting quality approvals sets us apart in the industry.
At Transparon, we place paramount importance on regulatory compliance and are dedicated to assisting our clients in fulfilling essential requirements. Our expertise encompasses a thorough comprehension of global regulatory frameworks, guidelines, and industry best practices. We maintain a vigilant stance, keeping abreast of regulatory alterations and advancements, which equips us to offer adept strategies for navigating intricate regulatory terrains and minimizing potential risks.
The regulatory framework for pharmaceuticals, cosmetics, and medical devices in India is primarily governed by the Drugs & Cosmetics Act, 1940, along with its corresponding rules from 1945. This comprehensive legislation delegates various responsibilities to both central and state regulators for the oversight and control of drugs, cosmetics, and medical devices within the country.
Specifically, the Drugs & Cosmetics Act, 1940, encompasses regulations related to the manufacturing, importation, sale, and distribution of medical devices. In addition to this act, the medical devices sector is subject to the provisions outlined in the Medical Devices Rules 2017, which came into effect on January 1, 2018. Furthermore, there have been subsequent amendments, such as the Medical Devices (Amendment) Rules 2020, which took effect on April 1, 2020, and any further amendments that may have been introduced thereafter.
These legislations collectively form the legal framework that governs the regulatory landscape for drugs, cosmetics, and medical devices in India, ensuring the safety, quality, and efficacy of products in these sectors.
Recognizing the paramount significance of client data security and confidentiality, Transparon is steadfast in its commitment to safeguarding sensitive information. We employ a robust framework of systems and procedures designed to fortify data protection. Our adherence to rigorous security protocols and industry-leading best practices guarantees the unwavering confidentiality and integrity of client data throughout our partnership.
Indeed, Transparon extends its services to clients on a global scale. Our extensive experience encompasses collaboration with regulatory authorities across the world, equipping us to offer comprehensive guidance on international regulatory prerequisites. With our global reach, we empower clients to navigate the complexities of market access in diverse countries and regions successfully.
Transparon primarily focuses its services on the pharmaceutical, biopharmaceutical, and medical devices sectors. We specialize in delivering regulatory solutions to enterprises engaged in the advancement, production, and distribution of pharmaceutical products. Our expertise spans a wide spectrum, encompassing small molecules, biologics, biosimilars, and advanced therapy products within these industries.
Indeed, Transparon possesses a wealth of experience in handling regulatory submissions for a multitude of countries. We are well-versed in guiding clients through the distinct regulatory prerequisites and guidelines inherent to various regions. Our proficiency extends to the meticulous preparation and submission of regulatory dossiers for a wide range of applications, including Market Authorization Applications (MAA), New Drug Applications (NDA Abbreviated), Abbreviated New Drug Applications (ANDA), and other global regulatory submissions.
At Transparon, we extend our regulatory compliance consulting services to encompass post-approval changes. Our team is well-equipped to aid clients in evaluating the potential implications of proposed alterations, crafting the requisite documentation, and efficiently navigating the regulatory landscape for submitting post-approval change applications. With our expertise, we ensure that changes are seamlessly implemented while adhering to all relevant regulations.
Certainly! Transparon is well-equipped to offer guidance on regulatory strategies tailored for product launches. Our approach involves a meticulous analysis of regulatory prerequisites, target markets, and the unique attributes of the product. This enables us to formulate customized strategies that enhance the prospects of a successful product launch and streamlined market entry. With our specialized expertise, clients benefit from adept navigation of the intricate global regulatory landscape, ensuring a seamless and effective launch journey.
Transparon maintains a vigilant approach to staying abreast of the most recent regulatory alterations. Our dedicated team is consistently engaged in the monitoring and tracking of regulatory changes, updates, and prevailing industry trends. We actively participate in regulatory networks, engage in industry conferences, and foster collaborative relationships with regulatory authorities. This concerted effort allows us to remain well-informed about the latest developments, enabling us to offer timely guidance and ensure unwavering compliance within the dynamic regulatory environment.